FGF23 and chronic kidney disease: The development of CKD-MBD was confirmed by the presence of high serum BUN, creatinine, and phosphate (Figure 9, B–D) as well as FGF23 and PTH levels (Supplemental Figure 16, A and B) without significant differences between the acute drug administration (vehicle versus SK-124) groups.